The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancerEmily E. Bosco, Erik S. Knudsen|Journal of Clinical Investigation|2006Cited by 192
Antitumor activity of AZD0754, a dnTGFβRII-armored, STEAP2-targeted CAR-T cell therapy, in prostate cancerPeter Zanvit, Emily E. Bosco|Journal of Clinical Investigation|2023Cited by 49
Rac1 targeting suppresses p53 deficiency–mediated lymphomagenesisEmily E. Bosco, Yi Zheng|Blood|2010Cited by 24
Preclinical evaluation of a GFRA1 targeted antibody-drug conjugate in breast cancerEmily E. Bosco, David A. Tice|Oncotarget|2018Cited by 17